{"organizations": [], "uuid": "23f65b18e86610428d2e87fb059cab2aaa670e65", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/6", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/19/globe-newswire-eyenovia-announces-conference-call-and-webcast-for-fourth-quarter-and-full-year-2017-financial-results.html", "country": "US", "domain_rank": 767, "title": "Eyenovia Announces Conference Call and Webcast for Fourth Quarter and Full Year 2017 Financial Results", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.001, "site_type": "news", "published": "2018-03-19T15:30:00.000+02:00", "replies_count": 0, "uuid": "23f65b18e86610428d2e87fb059cab2aaa670e65"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/19/globe-newswire-eyenovia-announces-conference-call-and-webcast-for-fourth-quarter-and-full-year-2017-financial-results.html", "ord_in_thread": 0, "title": "Eyenovia Announces Conference Call and Webcast for Fourth Quarter and Full Year 2017 Financial Results", "locations": [], "entities": {"persons": [{"name": "sean ianchulev", "sentiment": "none"}, {"name": "john gandolfo", "sentiment": "none"}], "locations": [{"name": "fourth quarter", "sentiment": "none"}, {"name": "eyenovia", "sentiment": "none"}, {"name": "united states", "sentiment": "none"}], "organizations": [{"name": "eyenovia inc.", "sentiment": "negative"}, {"name": "company", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- Eyenovia Inc. (“Eyenovia”) (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, announced today that the Company will release financial results for the fourth quarter and full year ended December 31, 2017 on Monday, April 2, 2018, before the market opens. Following the release, Dr. Sean Ianchulev, President and Chief Executive Officer, and John Gandolfo, Chief Financial Officer, will host a conference call to review the financial results.\nThe conference call is scheduled to begin at 8:30 am ET on Monday, April 2, 2018. Participants should dial 1-866-916-2921 (United States) or 1-210-874-7771 (International) with the conference code 3583799. A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at www.eyenoviabio.com .\nAfter the live webcast, the event will be archived on Eyenovia’s website for one year. In addition, a telephonic replay of the call will be available until April 9, 2018. The replay can be accessed by dialing 1-855-859-2056 (United States) or 1-404- 537-3406 (International) with confirmation code 3583799.\nAbout Eyenovia\nEyenovia is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for micro-therapeutics. Eyenovia’s pipeline is currently focused on the late-stage development of micro-therapeutics for glaucoma and other eye diseases.\nCompany Contact:\nEyenovia Inc.\nJohn Gandolfo\nChief Financial Officer\njgandolfo@eyenoviabio.com\nInvestor Contact:\nTram Bui / Alexander Lobo\nThe Ruth Group\nPhone: 646-536-7035/7037\nE-mail: tbui@theruthgroup.com / alobo@theruthgroup.com\nMedia Contact:\nThe Ruth Group\nKirsten Thomas\n508-280-6592\nkthomas@theruthgroup.com\nSource:Eyenovia, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=0lmprgaM6FQwKNPLqb1sx5RymLPnELIp8Uoy594YRKVrux5H1yfH63QwNo3xEjg2eU9cqolSDwOCLzyMCenlG2Fay_Un3AT-L5HqkGly4wQ=", "https://www.globenewswire.com/Tracker?data=WHs9ljjx3tOKYmpYbEFLWUhbWo1CY-sTuy-g8FPg7S3376HqCKU-VZ3U4fjmLnDBSTxhpRFjaZCXpdG0ihWL2el2pWeQLRBG2DZKMwAP7XQ=", "https://www.globenewswire.com/Tracker?data=F7C9076bJWrQWWv-583ONC5xuP30EOZ3oxbPXENKlwDeVEKijEgl7PGiXRQyBLB5TMMF6gblSjejrw30l9GgtIbXjigaiaRAzNwduSIi9Fs=", "https://www.globenewswire.com/Tracker?data=JHceKz2iDTRT_pZ0c-CdQ5gOUqGz-0MwWf5kLbK5xYt_m-n5vLwo8qi-FknKpYCODPK8kn-8GANA9sLMLgxS0oEMLDo94SbqqnOT4832mPs=", "https://www.globenewswire.com/NewsRoom/AttachmentNg/6c15f139-33a1-40ee-95e4-6c89edb40e5d", "https://www.globenewswire.com/Tracker?data=oWAh65ATZNIFTaisfUOPdnPSyCYnNHBIq2LdGgrzKL-QBW6CKHqj0UDjgNRpmwD0R7VFiIg7i7gq3LTGnwQDc0ANSTSxtccwrcpvt_ORoVM="], "published": "2018-03-19T15:30:00.000+02:00", "crawled": "2018-03-19T17:07:09.001+02:00", "highlightTitle": ""}